{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:29:54Z","timestamp":1774679394226,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jconrel.2020.05.025","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T11:49:56Z","timestamp":1589888996000},"page":"289-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts"],"prefix":"10.1016","volume":"324","author":[{"given":"Linlin","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhinong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yepiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beini","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-9728","authenticated-orcid":false,"given":"Hangxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.05.025_bb0005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Klaus","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nantod.2015.01.005","article-title":"Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation","volume":"10","author":"Talelli","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7150\/thno.8698","article-title":"Nanotheranostics-application and further development of nanomedicine strategies for advanced theranostics","volume":"4","author":"Muthu","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-018-0019-4","article-title":"A nanomedicine approach enables co-delivery of cyclosporin a and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer","volume":"3","author":"Han","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2018.05.008","article-title":"Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment","volume":"281","author":"Ganipineni","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0035","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-12-0372","article-title":"Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer","volume":"18","author":"Julien","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0040","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2019.07.006","article-title":"Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models","volume":"308","author":"Moro","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0050","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1021\/acsnano.5b01288","article-title":"IGF1 receptor targeted theranostic nanoparticles for targeted and image-guided therapy of pancreatic cancer","volume":"9","author":"Zhou","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0055","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrclinonc.2009.186","article-title":"Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer","volume":"7","author":"Bedard","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrd3254","article-title":"Cabazitaxel","volume":"9","author":"Galsky","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0070","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/1078-0432.CCR-12-1584","article-title":"Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?","volume":"18","author":"Mita","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0075","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0080","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1007\/s12274-018-2171-0","article-title":"Current taxane formulations and emerging cabazitaxel delivery systems","volume":"11","author":"Sun","year":"2018","journal-title":"Nano Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.29231","article-title":"CAST: a retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel","volume":"136","author":"Wissing","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0090","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1021\/ar200105p","article-title":"Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine","volume":"44","author":"Al-Jamal","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0100","doi-asserted-by":"crossref","first-page":"13248","DOI":"10.1039\/C5CC04643B","article-title":"Multifunctional nanoparticles: recent progress in cancer therapeutics","volume":"51","author":"Raju","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0105","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1039\/C4CC07644C","article-title":"Nanoparticle-blood interactions: the implications on solid tumour targeting","volume":"51","author":"James","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.biomaterials.2015.12.023","article-title":"In depth study on thermosensitive liposomes: optimizing formulations for tumor specific therapy and in vitro to in vivo relations","volume":"82","author":"Lokerse","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2016.08.036","article-title":"Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors","volume":"512","author":"Fang","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0120","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1158\/0008-5472.CAN-17-0984","article-title":"New generation nanomedicines constructed from self-assembling small molecule prodrugs alleviate cancer drug toxicity","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0125","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1039\/C8CC03763A","article-title":"Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin","author":"Fang","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0130","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1002\/adfm.201501953","article-title":"Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy","volume":"25","author":"Wang","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1126\/science.1255288","article-title":"Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins","volume":"345","author":"Pinot","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2014.12.027","article-title":"Esterase-activatable beta-lapachone prodrug micelles for NQO1-targeted lung cancer therapy","volume":"200","author":"Ma","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0145","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin b macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0150","doi-asserted-by":"crossref","first-page":"1804229","DOI":"10.1002\/adfm.201804229","article-title":"Structure-guided engineering of cytotoxic cabazitaxel for an adaptive nanoparticle formulation: enhancing the drug safety and therapeutic efficacy","volume":"28","author":"Wan","year":"2018","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0155","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.7150\/thno.20028","article-title":"Cancer nanomedicines stabilized by \u03c0-\u03c0 stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0160","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41419-019-1796-6","article-title":"CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells","volume":"10","author":"Ierano","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0165","doi-asserted-by":"crossref","first-page":"1802057","DOI":"10.1002\/advs.201802057","article-title":"Robust photodynamic therapy using 5-ALA-incorporated nanocomplexes cures metastatic melanoma through priming of CD4(+)CD8(+) double positive T cells","volume":"6","author":"Li","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0170","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1111\/cas.14171","article-title":"Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance","volume":"110","author":"Kita","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0175","article-title":"PIK3R1(W624R) is an actionable mutation in high grade serous ovarian carcinoma","volume":"9","author":"D'Ambrosio","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0185","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2016.02.027","article-title":"Let-7a suppresses macrophage infiltrations and malignant phenotype of Ewing sarcoma via STAT3\/NF-\u03baB positive regulatory circuit","volume":"374","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an inos(+)\/m1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Felix","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0195","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Toby","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0200","doi-asserted-by":"crossref","first-page":"11765","DOI":"10.1021\/jacs.9b04272","article-title":"Antitumor activity of 1,18-octadecanedioic acid-paclitaxel complexed with human serum albumin","volume":"141","author":"Callmann","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0205","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0210","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hepr.12621","article-title":"Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients","volume":"46","author":"Miyaki","year":"2016","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0215","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1021\/jacs.8b04400","article-title":"Supramolecular polymer-based nanomedicine: high therapeutic performance and negligible long-term immunotoxicity","volume":"140","author":"Yu","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0220","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1021\/jacs.8b12205","article-title":"Mitigation of hydrophobicity-induced immunotoxicity by sugar poly(orthoesters)","volume":"141","author":"Maiti","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0225","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0140-6736(00)02074-2","article-title":"The taxanes: an update","volume":"355","author":"Crown","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0230","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMe1003854","article-title":"Taxane-based chemotherapy for node-positive breast cancer-take-home lessons","volume":"362","author":"Ellis","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0235","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2013.08.010","article-title":"A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and beta-III tubulin mediated tumor drug resistance in vitro","volume":"341","author":"Cai","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0240","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0245","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","article-title":"Mechanisms of Taxol resistance related to microtubules","volume":"22","author":"Orr","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0250","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.biomaterials.2015.09.022","article-title":"Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment","volume":"73","author":"Assanhou","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0255","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1158\/0008-5472.CAN-18-0455","article-title":"A novel microtubule inhibitor overcomes multidrug resistance in tumors","volume":"78","author":"Ning","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0260","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.biotechadv.2014.10.011","article-title":"Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer","volume":"33","author":"Wang","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0265","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-12-3146","article-title":"Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors","volume":"19","author":"Vrignaud","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0270","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0275","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.06.007","article-title":"Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs","volume":"306","author":"Bavli","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0280","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1021\/ja0256212","article-title":"A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs","volume":"124","author":"Liu","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0285","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/ja909475m","article-title":"Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery","volume":"132","author":"Shen","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","article-title":"PEG-a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2018.08.002","article-title":"Degradable poly(ethylene glycol) (PEG)-based hydrogels for spatiotemporal control of siRNA\/nanoparticle delivery","volume":"287","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0300","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0305","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/acsami.9b20178","article-title":"Supramolecular engineering of molecular inhibitors in an adaptive cytotoxic nanoparticle for synergistic cancer therapy","volume":"12","author":"Han","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0310","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.7150\/thno.26161","article-title":"Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma","volume":"8","author":"Wang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0315","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2020.05.025_bb0320","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2017.03.395","article-title":"Targeting tumor associated macrophages (TAMs) via nanocarriers","volume":"254","author":"Singh","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0325","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1038\/onc.2015.14","article-title":"MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription","volume":"34","author":"Cheng","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2020.05.025_bb0330","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1535-6108(02)00153-8","article-title":"MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis","volume":"2","author":"Hiratsuka","year":"2002","journal-title":"Cancer Cell"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:50:17Z","timestamp":1759161017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920303023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":66,"alternative-id":["S0168365920303023"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.025","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}